The combination of chemotherapy and intraperitoneal MegaFas Ligand improves treatment of ovarian carcinoma

Détails

ID Serval
serval:BIB_1146F8ACDE04
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
The combination of chemotherapy and intraperitoneal MegaFas Ligand improves treatment of ovarian carcinoma
Périodique
Gynecologic Oncology
Auteur⸱e⸱s
Etter  A. L., Bassi  I., Germain  S., Delaloye  J. F., Tschopp  J., Sordat  B., Dupuis  M.
ISSN
0090-8258 (Print)
Statut éditorial
Publié
Date de publication
10/2007
Volume
107
Numéro
1
Pages
14-21
Notes
Journal Article --- Old month value: Oct
Résumé
OBJECTIVE: MegaFas Ligand (MFL) is a recombinant molecule that efficiently triggers apoptosis after binding to the Fas receptor expressed on target cells. The purpose of this study was to determine the potency of MFL in vitro and efficacy in vivo for intraperitoneal treatment of mice implanted with human ovarian carcinoma cells. METHODS: The potency of MFL was compared to that of other Fas agonists in a cytotoxicity assay on SKOV-3 cells. The potency of MFL was further determined by measuring apoptosis in combination with cisplatin. The efficacy of MFL was determined in vivo using peritoneal xenograft models of human ovarian carcinoma. RESULTS: In vitro, MFL induced significantly higher levels of apoptosis than other Fas agonists, and was able to overcome the resistance of the ovarian cancer cell line SKOV-3 to Fas agonist antibody. MFL exerted an enhanced cytotoxic effect when combined with platinum-based drugs, leading to significantly more apoptosis than by incubation with MFL or these drugs alone. Treatment of mice xenografted with SKOV-3 and HOC79 ovarian tumors by intraperitoneal administration of MFL alone or in combination with cisplatin resulted in a significant decrease in peritoneal tumor nodules and ascitic cells, and prolongation of survival as compared to non-treated mice. The beneficial effects of MFL treatment occurred in the absence of severe toxicity. CONCLUSION: MFL is a novel pro-apoptotic molecule that is able to efficiently induce apoptosis in ovarian cancer cells as well as to potentiate the activity of chemotherapeutic agents in vitro and in vivo.
Pubmed
Web of science
Création de la notice
24/01/2008 15:19
Dernière modification de la notice
20/08/2019 12:38
Données d'usage